Special Issue

Machine Learning in Oncology: Current Status and Future Perspectives

Message from the Guest Editors

Despite steady progress in basic and clinical research, cancer is still among the most challenging of human diseases. Artificial intelligence, a field of applied computer science, has accelerated the evolution of nearly every aspect of human lives, including healthcare. The application of data-driven machine learning (ML) and deep learning (DL) in translational research has shown great promise for advancing cancer diagnosis and treatment outcomes. ML-based algorithms for the analysis of radiological and histological images have been shown to enable detection and improve diagnostic accuracy in cancer. DL-based models using multi-omics and molecular datasets have provided opportunities to facilitate drug discovery and treatment. Validation and test datasets from cancer patients will enable the assessment of ML-created model effectiveness in oncology. The aim of this Special Issue is to collect articles that focus on machine learning for data analytics, with the goal of advancing the frontiers in clinical oncology and cancer research.

Guest Editors

Dr. Nelson Yee

Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033-0850, USA

Dr. Fenglong Ma

College of Information Sciences and Technology, Institute for Computational and Data Sciences, Pennsylvania State University, State College, PA 16802, USA

Deadline for manuscript submissions

closed (30 November 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/144194

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).